Article
Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2023
Cammann Clemens, Kulla Jonas, Wiebusch Lüder, Walz Christian, Zhao Fang, Lowinus Theresa, Topfstedt Eylin, Mishra Neha, Henklein Petra, Bommhardt Ursula, Bossaller Lukas, Hagemeier Christian, Schadendorf Dirk, Schmidt Boris, Paschen Annette, Seifert Ulrike
Abstract excerpt
Primary and acquired therapy resistance is a major problem in patients with BRAF-mutant melanomas being treated with BRAF and MEK inhibitors (BRAFI, MEKi). Therefore, development of alternative therapy regimes is still required. In this regard, new drug combinations targeting different pathways to induce apoptosis could offer promising alternative approaches. Here, we investigated the combination of proteasome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.